Skip to main content

Posters

March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: Patient Health Questionnaire-9 (PHQ-9) is a validated patient self-administrated tool of depression symptom severity. This study assessed the association between PHQ-9 severity and…
March 02, 2019
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Sexual dysfunction may be associated with major depressive disorder (MDD) or with antidepressant treatment. The antidepressant vortioxetine has shown low rates of treatment-emergent sexual…
March 02, 2019
This poster was presented at the 30th annual Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana. Traditional measures of MDD treatment response may miss meaningful changes for individual patients. A novel approach using a Goal Attainment Scale (GAS) Adapted for Depression (GAS-D)…
March 02, 2019
This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.
March 02, 2019
Background: Most people with depression do not achieve adequate treatment response. People’s perceptions of their depression and treatment outcomes are crucial to understanding challenges they endure in their disease. Objective: To gain an understanding of the experiences, health-related quality…
March 02, 2019
Predictive equations were derived to characterize the natural course of treatment-resistant depression (TRD). Patients experiencing major depressive disorder symptoms after failing two antidepressants are considered TRD. Statistical analyses were conducted using data from the Sequenced Treatment…
March 02, 2019
Objective: Identify patient and disease characteristics associated with greater likelihood of achieving response and remission with esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) in patients with treatment-resistant depression (TRD).
March 02, 2019
Background: Tardive dyskinesia (TD) is associated with antipsychotics. To date, predictive models assessing the clinical characteristics on TD risk have not been developed and validated in the US population. Objective: To develop a prediction model identifying factors associated with TD occurrence.
March 02, 2019
Aim:  Compare efficacy and safety of fixed doses of esketamine nasal spray plus oral antidepressant (AD) to oral AD plus placebo nasal spray for treatment-resistant depression (TRD). Methods:  Adults with moderate-to-severe depression and non-response to ≥2 ADs in the current depressive episode…
March 02, 2019
Objective: To evaluate the efficacy and tolerability of longer-term treatment with lurasidone in patients with major depressive disorder (MDD) with mixed features.
Back to Top